Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q8CB77

Entry ID Method Resolution Chain Position Source
AF-Q8CB77-F1 Predicted AlphaFoldDB

44 variants for Q8CB77

Variant ID(s) Position Change Description Diseaes Association Provenance
rs27604649 35 I>V No EVA
rs3388718116 38 I>N No EVA
rs3388718131 49 G>E No EVA
rs3410608093 50 K>T No EVA
rs3388723044 89 F>Y No EVA
rs3388723059 113 Q>H No EVA
rs3388718061 122 R>L No EVA
rs3388698490 148 S>N No EVA
rs3388715769 176 H>L No EVA
rs3394823813 200 Q>L No EVA
rs256603483 206 H>Q No EVA
rs3388710174 245 K>E No EVA
rs3388727770 247 K>M No EVA
rs223679721 250 A>V No EVA
rs3394905822 261 V>E No EVA
rs3394823754 261 V>L No EVA
rs234866788 269 A>T No EVA
rs3388727750 272 K>R No EVA
rs3388727782 283 S>N No EVA
rs3388725482 299 R>I No EVA
rs3388725499 306 K>E No EVA
rs3388723084 338 Q>* No EVA
rs3388718049 370 K>I No EVA
rs3388720346 372 R>T No EVA
rs3412731930 374 N>D No EVA
rs3388722055 375 A>P No EVA
rs13468011 382 P>L No EVA
rs3388698478 384 H>R No EVA
rs3388722572 416 K>R No EVA
rs239507697 422 T>A No EVA
rs3388722864 424 S>N No EVA
rs3388710176 441 S>I No EVA
rs3388718042 449 K>I No EVA
rs3388717065 456 N>K No EVA
rs3388698565 485 I>T No EVA
rs3388718087 583 C>Y No EVA
rs3388722080 591 I>L No EVA
rs27619971 605 L>F No EVA
rs3388723079 641 R>H No EVA
rs3388722833 642 L>P No EVA
rs3394931193 712 S>T No EVA
rs3394923408 713 S>I No EVA
rs3394879073 713 S>R No EVA
rs3388722546 760 A>T No EVA

No associated diseases with Q8CB77

3 regional properties for Q8CB77

Type Name Position InterPro Accession
domain F-box domain 565 - 609 IPR001810
domain Transcription elongation factor, TFIIS/CRSP70, N-terminal, sub-type 7 - 78 IPR003617
domain Transcription factor IIS, N-terminal 4 - 79 IPR017923

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
  • Localizes to sites of DNA damage
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

3 GO annotations of cellular component

Name Definition
elongin complex A transcription elongation factor complex that suppresses RNA polymerase II pausing, and may act by promoting proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site. Consists of a transcriptionally active Elongin A subunit (about 100 kDa) and two smaller Elongin B (about 18 kDa) and Elongin C (about 15 kDa) subunits.
site of DNA damage A region of a chromosome at which DNA damage has occurred. DNA damage signaling and repair proteins accumulate at the lesion to respond to the damage and repair the DNA to form a continuous DNA helix.
transcription elongation factor complex Any protein complex that interacts with RNA polymerase II to increase (positive transcription elongation factor) or reduce (negative transcription elongation factor) the rate of transcription elongation.

No GO annotations of molecular function

Name Definition
No GO annotations for molecular function

3 GO annotations of biological process

Name Definition
regulation of transcription by RNA polymerase II Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II.
transcription elongation by RNA polymerase II promoter The extension of an RNA molecule after transcription initiation and promoter clearance at an RNA polymerase II promoter by the addition of ribonucleotides catalyzed by RNA polymerase II.
transcription initiation at RNA polymerase II promoter A transcription initiation process that takes place at a RNA polymerase II gene promoter. Messenger RNAs (mRNA) genes, as well as some non-coding RNAs, are transcribed by RNA polymerase II.

2 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q14241 ELOA Elongin-A Homo sapiens (Human) PR
Q8IYF1 ELOA2 Elongin-A2 Homo sapiens (Human) PR
10 20 30 40 50 60
MAAESALQVV EKLQARLAAN PDPKKLLKYL KKLSILPITV DILVETGVGK TVNSFRKHEQ
70 80 90 100 110 120
VGNFARDLVA QWKKLVPVER NSEAEDQDFE KNNSRKRPRD ALQREEELEG NYQESWKPSG
130 140 150 160 170 180
SRSYSPEHRQ KKHKKLSEPE RPHKVAHSHE KRDERKRCHK VSPPYSSDPE SSDYGHVQSP
190 200 210 220 230 240
PPSSPHQMYT DLSRSPEEDQ EPIISHQKPG KVHSNTFQDR LGVSHLGEQG KGAVSHHKQH
250 260 270 280 290 300
RSSHKEKHPA DAREDEKISA VSREKSHKAS SKEESRRLLS GDSAKEKLPS SVVKKDKDRE
310 320 330 340 350 360
GSSLKKKFSP ALDVASDNHF KKPKHKDSEK AKSDKNKQSV DGVDSGRGTG DPLPKAKEKV
370 380 390 400 410 420
PNHLKAQEGK VRTNADGKSA GPLHPKAEET DVDDEFERPT MSFESYLSYD QPRKKKKKVV
430 440 450 460 470 480
KTSSTALGEK GLKKKDSKST SKNLNSAQKL PKVNENKSEK LQPAGAEPTR PRKVPTDVLP
490 500 510 520 530 540
ALPDIPLPAI HANYRPLPSL ELIPSFQPKR KAFSSPQEEE EAGFTGRRMN SKMQVYSGSK
550 560 570 580 590 600
CAYLPKMMTL HQQCIRVLKN NIDSIFEVGG VPYSVLEPVL ERCTPDQLYR IEECNHVLIE
610 620 630 640 650 660
ETDQLWKVHC HRDFKEERPE EYESWREMYL RLQDAREQRL RLLTNNIRSA HANKPKGRQA
670 680 690 700 710 720
KMAFVNSVAK PPRDVRRRQE KFGTGGAAVP EKVRIKPAPY TTGSSHVPAS NSSSNFHSSP
730 740 750 760 770
EELAYDGPST SSAHLAPVAS SSVSYDPRKP AVKKIAPMMA KTIKAFKNRF SRR